Compare BioNTech SE - ADR (BNTX) vs Canadian National Railway Co. (CNI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Canadian National Railway Co. — how do they compare? BioNTech SE - ADR trades at $93.16 (market cap $23.31B), while Canadian National Railway Co. trades at $126.29 (market cap $76.28B). The key difference: Canadian National Railway Co. is far larger — about 3.3× BioNTech SE - ADR's market cap, and Canadian National Railway Co. pays a 2.06% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | CNI | |
|---|---|---|
Market Cap | $23.31B | $76.28B |
Sector | Health | Industrials |
52-Week High | $119.34 | $130.58 |
52-Week Low | $83.89 | $90.91 |
Enterprise Value | $6.60B | $92.31B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Canadian National Railway (CNI) trades at $125.14, down 1.15% with a bearish technical signal. The company reported strong Q2 2026 results with EPS of $1.50 beating estimates by 7.9% and raised full-year guidance, driven by record grain volumes and improved operational efficiency. Fundamentals show solid profitability with 26.92% net margin and 22.02% ROE, though valuation multiples appear elevated with P/E of 22.62. Recent news highlights continued infrastructure investment and customer growth projects exceeding $2 billion in 2025.
CNI presents a mixed outlook with strong operational execution offset by valuation concerns. The 21.8% upside to consensus price target of $152.38 offers potential, but rising debt levels and competitive pressures pose risks. Analyst sentiment is cautious with 60.79% hold ratings, suggesting waiting for clearer evidence of sustained earnings growth before committing new capital.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →
